Literature DB >> 23035072

Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod.

John N Ratchford1, Kathleen Costello, Daniel S Reich, Peter A Calabresi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23035072      PMCID： PMC3484989          DOI： 10.1212/WNL.0b013e3182735d00

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  3 in total

1.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

2.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

Review 3.  The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features.

Authors:  M A Nagel; R J Cohrs; R Mahalingam; M C Wellish; B Forghani; A Schiller; J E Safdieh; E Kamenkovich; L W Ostrow; M Levy; B Greenberg; A N Russman; I Katzan; C J Gardner; M Häusler; R Nau; T Saraya; H Wada; H Goto; M de Martino; M Ueno; W D Brown; C Terborg; D H Gilden
Journal:  Neurology       Date:  2008-03-11       Impact factor: 9.910
  3 in total
  24 in total

Review 1.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

Authors:  Mike P Wattjes; Àlex Rovira; David Miller; Tarek A Yousry; Maria P Sormani; Maria P de Stefano; Mar Tintoré; Cristina Auger; Carmen Tur; Massimo Filippi; Maria A Rocca; Franz Fazekas; Ludwig Kappos; Chris Polman
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

2.  Recurrent varicella following steroids and fingolimod in a Multiple Sclerosis patient.

Authors:  D Ferraro; S De Biasi; F Vitetta; A M Simone; L Federzoni; V Borghi; A Cossarizza; P F Nichelli; P Sola
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-27       Impact factor: 4.147

Review 3.  Safety, tolerability, and efficacy of oral therapies for relapsing-remitting multiple sclerosis.

Authors:  Jiwon Oh; Paul W O'Connor
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

Review 4.  [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors:  L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

5.  Initiating oral fingolimod treatment in patients with multiple sclerosis.

Authors:  Barry A Singer
Journal:  Ther Adv Neurol Disord       Date:  2013-07       Impact factor: 6.570

Review 6.  Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?

Authors:  Shani Witman Tsur; Eli Adrian Zaher; Meydan Tsur; Karolina Kania; Alicja Kalinowska-Łyszczarz
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

7.  Adverse Effects of Immunosuppression: Infections.

Authors:  Guy Handley; Jonathan Hand
Journal:  Handb Exp Pharmacol       Date:  2022

Review 8.  Targeting cells in motion: migrating toward improved therapies.

Authors:  Jason W Griffith; Andrew D Luster
Journal:  Eur J Immunol       Date:  2013-05-13       Impact factor: 5.532

Review 9.  Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Authors:  Wolfgang Brück; Raff Gold; Brett T Lund; Celia Oreja-Guevara; Alexandre Prat; Collin M Spencer; Lawrence Steinman; Mar Tintoré; Timothy L Vollmer; Martin S Weber; Leslie P Weiner; Tjalf Ziemssen; Scott S Zamvil
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

Review 10.  Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Authors:  Joachim Havla; Ingo Kleiter; Tania Kümpfel
Journal:  Ther Clin Risk Manag       Date:  2013-10-03       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.